ACT-334441 + atenolol

**ACT-334441 (Cenerimod) + atenolol** is a combination therapy consisting of two separate drugs. ACT-334441, also known as cenerimod, is a potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist, currently in clinical trials for systemic lupus erythematosus and investigated for its immunomodulatory properties and biological activity[1][2][4][5]. Cenerimod selectively modulates S1P1, resulting in sequestration of lymphocytes in lymphoid tissues and reduction of their circulation, thus reducing autoimmune activity. Atenolol is a cardioselective β-1 adrenergic receptor antagonist (beta-blocker), widely approved and used to treat hypertension, angina pectoris, and acute myocardial infarction, with off-label uses in arrhythmias, migraine prophylaxis, and other conditions[3]. Combination studies have been conducted to evaluate drug-drug interactions, particularly for cardiovascular and immune-related safety and pharmacokinetics[1][4].

Brand names

Cenerimod

Other names

ACT-334441ACT334441ACT 334441Cenerimodatenolol